Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.44 |
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368872 | 0.92 | PPARG (0.44) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL5412443 | 0.88 | PDE3B (0.43) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL6170153 | 0.86 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL5414898 | 0.85 | PDE3B (0.45) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL2330018 | 0.85 | PDE3B (0.48) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL6168443 | 0.83 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2ALTB4R | |
| SCHEMBL2326969 | 0.83 | PDE3B (0.48) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL5410430 | 0.82 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2ALTB4R | |
| SCHEMBL5420262 | 0.82 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL5417467 | 0.82 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2ALTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| US-6903126-B2 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2005-06-07 | — | — | US | claimed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | claimed |
| US-7196202-B2 | 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | US | disclosed |
| US-6903126-B2 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1404656-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | disclosed |
| WO-2003006438-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, ARG1 | PDE3B 471/4885PDE3A 476/4885P2RY12 640/4885 |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, CYBB | PDE3B 323/4885PDE3A 386/4885P2RY12 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.